Filana Therapeutics, Inc. FLNA · SEC Filings

website

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagn...

Price0.4923

Market Cap24.65 M

Float48.91 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Filana Therapeutics Reports Q3 2026 Financial Results and Prepares for Phase 2a Simufilam Trial

Nov 5, 2026

8-K

U.S. Court of Appeals Vacates Class Certification in Filana Therapeutics Securities Class Action

Oct 20, 2026

8-K

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam for Phase 2a Study in TSC-Related Epilepsy

Sep 22, 2026

8-K

Filana Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice

Sep 18, 2026

8-K

Filana Therapeutics Reports Q2 2026 Financial Results and Business Update

Jul 29, 2026

8-K

Filana Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 15, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

S-3

November 2025 SHELF and ATM

Nov 12, 2025

8-A12B

Warrants to Purchase Shares of Common Stock, Expiring on or before November 15, 2024

Jan 3, 2024

8-A12G

Warrants to Purchase Shares of Common Stock, Expiring on or before November 15, 2024

Jan 2, 2024

S-3ASR

Registration

May 1, 2023

S-8

Registration

Jun 10, 2022

S-3ASR

Registration-

Feb 10, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 14, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 3, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 27, 2023

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 16, 2023

Ownerships

TYPE

HEADLINE

FILED AT

Barry Richard (Reporting)

Oct 1, 2026

Barry Richard (Reporting)

Sep 30, 2026

Anderson Robert Eugene Jr (Reporting)

Nov 25, 2025

Barry Richard (Reporting)

Nov 24, 2025

Barry Richard (Reporting)

Nov 20, 2025

S-3

Form S-3 - Registration statement under Securities Act of 1933

Nov 12, 2025

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 8, 2025

CORRESP

Form CORRESP - Correspondence

Dec 3, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 14, 2023

CORRESP

Form CORRESP - Correspondence

Aug 10, 2023

LETTER

Form UPLOAD - SEC-generated letter

Jul 28, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

May 6, 2020